Bone morphogenetic protein receptor type I (BMPRI) (BMPRI)

Bone morphogenetic protein receptor type I (BMPRI) refers to a family of transmembrane serine/threonine kinases, including BMPR1A (ALK3), BMPR1B (ALK6), ACVR1 (ALK2), and ACVRL1 (ALK1), which are central to the transforming growth factor-beta (TGF-beta) signaling superfamily [1.3.1, 1.3.4]. These receptors function by forming heterotetrameric complexes with type II receptors upon binding to bone morphogenetic proteins (BMPs), triggering the phosphorylation of SMAD1/5/8 proteins to regulate gene expression [1.3.3, 1.4.5]. BMPRI signaling is critical for embryonic development, skeletal homeostasis, and the regulation of iron metabolism through hepcidin expression [1.3.1, 1.1.3]. Dysregulation of these receptors is implicated in various pathologies, such as fibrodysplasia ossificans progressiva (FOP), juvenile polyposis syndrome, and certain cancers where they can act as either oncogenes or tumor suppressors [1.4.2, 1.4.5]. Pharmacological targeting of BMPRI is an active area of research, with small-molecule inhibitors like momelotinib and saracatinib being explored for treating anemia of inflammation and FOP [1.1.2, 1.1.3, 1.4.1]. These therapeutic interventions aim to selectively block the kinase activity of specific type I receptors to restore normal signaling balance [1.2.3, 1.4.2]. However, achieving selectivity among the different ALK family members remains a significant challenge in drug development [1.4.1, 1.4.3].

Other names

BMPR-IActivin receptor-like kinaseALK1ALK2ALK3ALK6BMPR1ABMPR1BACVR1ACVRL1

Inhibition of the intracellular serine/threonine kinase domain of type I BMP receptors, which prevents the phosphorylation of receptor-regulated SMAD proteins (SMAD1, SMAD5, and SMAD8) and subsequent downstream gene transcription.